Amedica to Present 24-Month CASCADE Clinical Trial Results

SALT LAKE CITY, Feb. 18, 2016 -- Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced that it will host a conference call and live webcast to present the 24-month clinical results from a blinded, randomized clinical trial (CASCADE) that compared spinal fusion between its composite silicon nitride fusion devices with a central, cancellous ceramic core, to the industry standard of PEEK spacers filled with bone autograft.

Principal investigator Mark P. Arts, M.D., Ph.D., Neurosurgeon from the Medical Center Haaglanden, The Hague, Netherlands will present the data and Dr. Sonny Bal, Chairman and CEO of Amedica Corporation will discuss its impact on the business. Details related to this call are as follows:

For those who are not available to listen to the live webcast, the call will be archived on the investor relations section of the Amedica website under Events & Presentations.

About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Contacts:
Mike Houston
VP, Commercialization
801-839-3534
[email protected]

Robert Haag
IRTH Communications
866-976-4784
[email protected]